Correa Ricardo, Zilbermint Mihail, Berthon Annabel, Espiard Stephanie, Batsis Maria, Papadakis Georgios Z, Xekouki Paraskevi, Lodish Maya B, Bertherat Jerome, Faucz Fabio R, Stratakis Constantine A
Section on Endocrinology and GeneticsProgram on Developmental Endocrinology and Genetics, <ce:italic>Eunice Kennedy Shriver</ce:italic> National Institute of Child Health and Human Development, National Institutes of Health, NIH-Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC1103, Bethesda, Maryland 20892, USADepartment of Radiology and Imaging SciencesNational Institutes of Health (NIH), Clinical Center, Bethesda, Maryland 20892, USADepartment of EndocrinologyMetabolism, and Diabetes, Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 1016, Institut Cochin, Centre National de la Recherche Scientifique (CNRS) UMR 8104, 75014 Paris, FranceGroup for Advanced Molecular InvestigationGraduate Program in Health Science, Medical School, Pontificia Universidade Catolica do Paraná, Curitiba, Paraná, Brazil.
Section on Endocrinology and GeneticsProgram on Developmental Endocrinology and Genetics, <ce:italic>Eunice Kennedy Shriver</ce:italic> National Institute of Child Health and Human Development, National Institutes of Health, NIH-Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC1103, Bethesda, Maryland 20892, USADepartment of Radiology and Imaging SciencesNational Institutes of Health (NIH), Clinical Center, Bethesda, Maryland 20892, USADepartment of EndocrinologyMetabolism, and Diabetes, Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 1016, Institut Cochin, Centre National de la Recherche Scientifique (CNRS) UMR 8104, 75014 Paris, FranceGroup for Advanced Molecular InvestigationGraduate Program in Health Science, Medical School, Pontificia Universidade Catolica do Paraná, Curitiba, Paraná, Brazil Section on Endocrinology and GeneticsProgram on Developmental Endocrinology and Genetics, <ce:italic>Eunice Kennedy Shriver</ce:italic> National Institute of Child Health and Human Development, National Institutes of Health, NIH-Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC1103, Bethesda, Maryland 20892, USADepartment of Radiology and Imaging SciencesNational Institutes of Health (NIH), Clinical Center, Bethesda, Maryland 20892, USADepartment of EndocrinologyMetabolism, and Diabetes, Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 1016, Institut Cochin, Centre National de la Recherche Scientifique (CNRS) UMR 8104, 75014 Paris, FranceGroup for Advanced Molecular InvestigationGraduate Program in Health Science, Medical School, Pontificia Universidade Catolica do Paraná, Curitiba, Paraná, Brazil
Eur J Endocrinol. 2015 Oct;173(4):435-40. doi: 10.1530/EJE-15-0205. Epub 2015 Jul 10.
Primary macronodular adrenal hyperplasia (PMAH) is a rare type of Cushing's syndrome (CS) that results in increased cortisol production and bilateral enlargement of the adrenal glands. Recent work showed that the disease may be caused by germline and somatic mutations in the ARMC5 gene, a likely tumor suppressor gene (TSG). We investigated 20 different adrenal nodules from one patient with PMAH for ARMC5 somatic sequence changes.
All of the nodules were obtained from a single patient who underwent bilateral adrenalectomy. DNA was extracted by standard protocol and the ARMC5 sequence was determined by the Sanger method.
Sixteen of 20 adrenocortical nodules harbored, in addition to what appeared to be the germline mutation, a second somatic variant. The p.Trp476* sequence change was present in all 20 nodules, as well as in normal tissue from the adrenal capsule, identifying it as the germline defect; each of the 16 other variants were found in different nodules: six were frame shift, four were missense, three were nonsense, and one was a splice site variation. Allelic losses were confirmed in two of the nodules.
This is the most genetic variance of the ARMC5 gene ever described in a single patient with PMAH: each of 16 adrenocortical nodules had a second new, 'private,' and--in most cases--completely inactivating ARMC5 defect, in addition to the germline mutation. The data support the notion that ARMC5 is a TSG that needs a second, somatic hit, to mediate tumorigenesis leading to polyclonal nodularity; however, the driver of this extensive genetic variance of the second ARMC5 allele in adrenocortical tissue in the context of a germline defect and PMAH remains a mystery.
原发性大结节性肾上腺增生(PMAH)是库欣综合征(CS)的一种罕见类型,可导致皮质醇分泌增加及双侧肾上腺增大。近期研究表明,该疾病可能由ARMC5基因的种系和体细胞突变引起,ARMC5基因可能是一种肿瘤抑制基因(TSG)。我们对一名PMAH患者的20个不同肾上腺结节进行了ARMC5体细胞序列变化的研究。
所有结节均取自一名接受双侧肾上腺切除术的患者。采用标准方案提取DNA,并通过桑格法测定ARMC5序列。
20个肾上腺皮质结节中有16个除了存在似乎是种系突变外,还存在第二个体细胞变异。p.Trp476*序列变化存在于所有20个结节以及肾上腺包膜的正常组织中,确定其为种系缺陷;其他16个变异分别存在于不同的结节中:6个为移码突变,4个为错义突变,3个为无义突变,1个为剪接位点变异。在其中两个结节中证实存在等位基因缺失。
这是在一名PMAH患者中所描述的ARMC5基因最丰富的遗传变异:16个肾上腺皮质结节中的每一个除了种系突变外,都有第二个新的、“私人的”且在大多数情况下完全失活的ARMC5缺陷。数据支持ARMC5是一种肿瘤抑制基因的观点,其需要第二次体细胞打击来介导导致多克隆结节形成的肿瘤发生;然而,在种系缺陷和PMAH背景下,肾上腺皮质组织中第二个ARMC5等位基因这种广泛遗传变异的驱动因素仍是一个谜。